Author

Atsushi Satō

Observed names: A. Sato, Atsushi Sato, Sato, Atsushi

Institution: Hirosaki University

Observed institutions: Kurume University, SHOWA Medical University, Hirosaki University, Tohoku University, Mitsubishi UFJ Research & Consulting (Japan), Osaka National Hospital, Aomori Prefectural Central Hospital, The Cancer Institute Hospital, Sendai Kousei Hospital

ORCID: 0000-0002-5417-6701

Observed ORCID: 0000-0002-5417-6701

OpenAlex ID: A5084969376

Assessing the contribution of harvested wood products under greenhouse gas estimation: accounting under the Paris Agreement and the potential for double-counting among the choice of approaches

2019 · Atsushi Sato, Yukihiro Nojiri · Carbon Balance and Management · 52

Options for including land use in a climate agreement post-2012: improving the Kyoto Protocol approach

2007 · Bernhard Schlamadinger, Tracy Johns, et al. · Environmental Science & Policy · 51

Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer

2022 · Ken Ito, Satoshi Yuki, et al. · Supportive Care in Cancer · 11

Phase II study of raltitrexed (Tomudex®) in chemotherapy-pretreated patients with advanced colorectal cancer

1999 · Atsushi Sato, Minoru Kurihara, et al. · Anti-Cancer Drugs · 11

Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201)

2026 · Kazuaki Harada, Shinya Kajiura, et al. · Supportive Care in Cancer · 2

A multicenter retrospective study on the clinical features of patients with human epidermal growth factor receptor 2-positive colorectal cancer (HGCSG2304)

2026 · Shiho Kaneko, Kentaro Sawada, et al. · International Journal of Clinical Oncology

A Simplified Limited-Sampling Strategy for Accurate Prediction of Doxorubicin and Doxorubicinol Exposure

2026 · Keigo Saito, Takenori Takahata, et al. · Therapeutic Drug Monitoring

A randomized phase III study of gemcitabine plus cisplatin with S-1 versus gemcitabine plus cisplatin with immune checkpoint inhibitor in unresectable biliary tract cancer.

2026 · Hiroto Matsui, Takeshi Terashima, et al. · Journal of Clinical Oncology

A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903)

2026 · Yasuyuki Kawamoto, Kentaro Sawada, et al. · Gastric Cancer

Psoas muscle index as an independent prognostic factor in patients with unresectable pancreatic cancer: A retrospective analysis

2026 · Chen, Yu, Tatsuo, Soichiro, et al. · Institutional Repositories DataBase (IRDB)

RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational research

2026 · Shonosuke Wakayama, Shin Takahashi, et al. · Scientific Reports

HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib

2018 · Y. Shindo, S. Yuki, et al. · Annals of Oncology

HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab

2017 · Y. Kawamoto, S. Yuki, et al. · Annals of Oncology

Additional file 1: of Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer

2016 · Komatsu, Yoshito, Ishioka, Chikashi, et al. · Figshare

Works count: 17

Citation count: 127

H-index: 4

I10-index: 4